Patents by Inventor Aurelia Haller
Aurelia Haller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9376726Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.Type: GrantFiled: May 5, 2014Date of Patent: June 28, 2016Assignee: Erasmus University Medical Center RotterdamInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Aurelia Haller, Roderick Tang
-
Publication number: 20140295409Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.Type: ApplicationFiled: May 5, 2014Publication date: October 2, 2014Inventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Aurelia Haller, Roderick Tang
-
Patent number: 8821892Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: January 8, 2013Date of Patent: September 2, 2014Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Patent number: 8722341Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV). Described are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. Also described is mammalian MPV, subgroups and variants thereof, and genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods is provided. Nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus are described. Also provided are chimeric or recombinant viruses encoded by said nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.Type: GrantFiled: December 31, 2008Date of Patent: May 13, 2014Assignees: ViroNovative B.V., MedImmune Vaccines, Inc.Inventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
-
Publication number: 20130309265Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: ApplicationFiled: January 8, 2013Publication date: November 21, 2013Applicant: GLOBEIMMUNE, INC.Inventors: Richard Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Patent number: 8388980Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: December 4, 2009Date of Patent: March 5, 2013Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Publication number: 20120294890Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: December 19, 2011Publication date: November 22, 2012Applicant: Medlmmune, LLCInventors: Aurelia Haller, Kathleen L. Coelingh
-
Publication number: 20120045471Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: October 20, 2010Publication date: February 23, 2012Applicant: MedImmune, LLCInventors: Aurelia Haller, Kathleen Coelingh
-
Patent number: 8084037Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: January 27, 2010Date of Patent: December 27, 2011Assignee: MedImmune, LLCInventors: Aurelia Haller, Kathleen Coelingh
-
Patent number: 8007816Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: August 22, 2008Date of Patent: August 30, 2011Assignee: GlobeImmune, Inc.Inventors: Richard C Duke, Alex Franzusoff, Aurelia Haller, Thomas H King
-
Publication number: 20100297730Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: December 22, 2008Publication date: November 25, 2010Inventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
-
Publication number: 20100196411Abstract: The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.Type: ApplicationFiled: April 16, 2010Publication date: August 5, 2010Applicant: Globelmmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King, Yingnian Lu, Victoria Kelley Hodson
-
Publication number: 20100150963Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: ApplicationFiled: December 4, 2009Publication date: June 17, 2010Applicant: Globelmmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Patent number: 7736642Abstract: The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.Type: GrantFiled: February 2, 2007Date of Patent: June 15, 2010Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King, Yingnian Lu, Victoria Kelley Hodson
-
Publication number: 20100143407Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.Type: ApplicationFiled: December 31, 2008Publication date: June 10, 2010Inventors: Ronaldus Adrianus Maria Fouchier, Benadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
-
Publication number: 20100119547Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: January 27, 2010Publication date: May 13, 2010Applicant: MedImmune, LLCInventors: Aurelia Haller, Kathleen L. Coelingh
-
Patent number: 7678376Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: GrantFiled: January 16, 2008Date of Patent: March 16, 2010Assignee: MedImmune, LLCInventors: Aurelia Haller, Kathleen Coelingh
-
Patent number: 7632511Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: December 31, 2006Date of Patent: December 15, 2009Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Patent number: 7625569Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: December 31, 2006Date of Patent: December 1, 2009Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Publication number: 20090263883Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.Type: ApplicationFiled: April 24, 2009Publication date: October 22, 2009Applicant: MEDIMMUNE, LLCInventors: Aurelia Haller, Kathleen Coelingh